安罗替尼治疗老年肺癌患者疗效及安全性分析  

Clinical efficacy and safety analysis of anlotinib in the treatment of elderly patients with lung cancer

作　　者：王婧[1] 马晓 尚昆[1] 曹邦伟[1] WANG Jing;MA Xiao;SHANG Kun;CAO Bangwei(Department of Oncology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院肿瘤科,北京100050

出　　处：《临床与病理杂志》2022年第4期799-805,共7页Journal of Clinical and Pathological Research

基　　金：北京市临床重点专科基金(2018-2020)。

摘　　要：目的:探讨安罗替尼对老年肺癌患者疗效及安全性分析。方法:回顾性收集2018年12月1日至2020年5月1日首都医科大学附属北京友谊医院收治的晚期肺癌老年患者73例,均使用安罗替尼治疗,观察患者无进展生存期(progression-free survival,PFS)、总生存期(overall survival,OS)以及药物不良反应情况。结果:安罗替尼的客观有效率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)分别为8.22%、56.16%,PFS为5.2个月,OS为11.2个月。Cox比例风险模型单因素分析显示年龄、病理类型、治疗线数、安罗替尼的使用剂量是影响老年肺癌患者PFS的因素(P<0.05),性别、病理类型、治疗线数、用药剂量是影响OS的因素,差异均有统计学意义(P<0.05)。多因素分析显示肿瘤分期是影响老年患者中位PFS、OS的因素。安罗替尼的不良反应主要为乏力(27/73,36.90%)、胃肠道反应(24/73,28.70%)、出血(8/73,11%)、高血压(6/73,8.2%)、蛋白尿(5/73,6.8%)等。结论:安罗替尼对老年晚期肺癌患者的疗效好,可改善患者预后,延长生存期,不良反应可控,使用方便,值得临床推广。Objective:To evaluate the efficacy and safety of anlotinib for elderly patients with lung cancer.Methods:Seventythree elderly patients with advanced lung cancer admitted to our hospital from December 1,2018 to May 1,2020,all of whom were treated with anlotinib,were evaluated retrospectively for progression-free survival(PFS),overall survival(OS),and adverse drug reactions.Results:The objective response rate was 8.22%(6/73)and the disease control rate was 56.16%(41/73).The median PFS and OS were 5.2 months and 11.2 months,respectively.Univariate analysis of a Cox proportional risk model showed that age,pathological type,treatment lines,and anlotinib dosage were factors that affected PFS(P<0.05).Gender,pathological type,treatment lines,and dosage affected OS(P<0.05).Multivariate Cox prognostic analysis showed that clinical stage was an independent predictor of PFS and OS.Adverse reactions were primarily grade 1-2.The most prevalent adverse reactions were fatigue(27/73,36.90%),gastrointestinal reactions(24/73,28.70%),hemorrhage(8/73,11%),hypertension(6/73,8.2%),and proteinuria(5/73,6.8%).Conclusion:Anlotinib displayed good short-term efficacy with demonstrable survival benefits,and excellent safety with tolerable adverse reactions.

关 键 词：老年 肺癌 安罗替尼 有效性 安全性 

分 类 号：R734.2[医药卫生—肿瘤]